Sharetreck – Tracking Genomic Investments & clinical trials for HIV.

In the dynamic landscape of healthcare and therapeutics, the convergence of Genomics and Artificial Intelligence (AI) has ignited a revolution in digital biology, with groundbreaking advancements in whole genome sequencing leading the charge. This transformative integration is reshaping our understanding and treatment of diseases, necessitating a closer look at the essence of AI, its applications across industries, and its pivotal role in genomics companies.

Understanding AI: AI, defined as a science and computational technology inspired by human nervous systems, operates distinctly to mimic and sometimes surpass human intelligence. Built as software or tools, AI processes large, well-explained datasets crucial for understanding human analytical processes. In the ever-evolving field of AI, scientists continually develop new techniques and tools to keep pace with technological advancements.

Machine Learning and Deep Learning: Machine Learning (ML) and deep learning are integral components of AI, frequently mentioned in genomics contexts. ML enables machines to learn from datasets without explicit programming, operating in either a supervised or unsupervised manner. Deep learning, a modern ML technique, imitates human brain neurons, finding patterns in large datasets deeply.

Genomics and AI/ML Integration: Two decades post the landmark completion of the draft human genome sequence, genomics researchers face an explosion of data. AI/ML-based computational tools become imperative for handling, extracting, and interpreting valuable information within this vast trove of data. The cost of sequencing a human genome is decreasing, yet volumes of sequencing data are exponentially increasing.

Ways AI/ML Are Used in Genomics: Despite being in its early stages, the integration of AI/ML tools in genomics is proving highly beneficial. Applications range from facial analysis AI for identifying genetic disorders to machine learning techniques for cancer identification and predicting disease progression. AI/ML methods are also employed in variant identification, improving gene editing tools like CRISPR and aiding predictions in influenza and SARS-CoV-2 virus genomes.

Additional Information on Whole Genome Sequencing: Advancements in whole genome sequencing have sparked a revolution in digital biology, with genomics programs gaining momentum globally. The declining cost of high-throughput, next-generation sequencing has made whole genome sequencing a fundamental step in clinical workflows and drug discovery. However, sequencing is just the beginning; analyzing sequencing data demands accelerated compute, data science, and AI to unlock the full potential of the human genome.

Explosion in Bioinformatics Data: Sequencing an individual’s whole genome generates approximately 100 gigabytes of raw data, doubling after complex algorithms and applications like deep learning are applied. As the cost of sequencing decreases, the volume of data is exponentially increasing. An estimated 40 exabytes will be required to store all human genome data by 2025, emphasizing the need for AI/ML-based tools to handle and interpret this massive influx of data.

Accelerated Genome Sequencing Analysis Workflows: Genome sequencing analysis is intricate and computationally intensive, demanding new computing approaches as Moore’s Law nears its end. Deep learning is becoming vital for base calling within genomic instruments, enhancing accuracy and speeding up the genomics workflow. GPU-optimized alignment technologies and dynamic programming algorithms like BWA-MEM and Smith-Waterman contribute to rapid and accurate data analysis.

Uncovering Genetic Variants: One of the critical stages of sequencing projects is variant calling, where AI/ML-optimized callers like GATK and deep learning-based variant callers such as DeepVariant increase speed and accuracy. Secondary analysis software in NVIDIA’s Parabricks suite accelerates these variant callers significantly, reducing runtime and improving overall efficiency.

Accelerating the Next Wave of Genomics with NVIDIA and AMD: NVIDIA is at the forefront of enabling the next wave of genomics, powering sequencing platforms with accelerated AI base calling and variant calling. Collaborations with biotech companies like PacBio and Oxford Nanopore Technologies showcase the transformative impact of AI-accelerated genomics. Simultaneously, AMD’s machine learning (ML) inference is making waves in healthcare, facilitating the early detection of critical ailments by identifying anomalies in various medical imaging domains, including X-rays, ultrasound, digital pathology, dermatology, and ophthalmology. Beyond diagnostics, AMD’s ML capabilities extend to surgical tool guidance, drug discovery, and genome analysis. The partnership between NVIDIA and AMD, supported by their partner ecosystems, promises significant advancements across a spectrum of healthcare applications, underlining the potential to revolutionize healthcare design methodologies and provide comprehensive solutions.

In conclusion, the symbiosis of Genomics and AI, particularly powered by NVIDIA’s and AMD’s advancements, is not merely a scientific collaboration; it’s a driving force propelling genomics into a new era of accessibility, accuracy, and affordability. The seamless integration of these technologies holds immense promise for unraveling the mysteries within the human genome, ultimately reshaping the landscape of healthcare and therapeutics.